目的 探討地奧司明聯(lián)合阿加曲班治療下肢深靜脈血栓的臨床療效。方法 選擇2021年6月-2022年6月在晉城市人民醫(yī)院治療的80例下肢深靜脈血栓患者,隨機法分為對照組(40例)和治療組(40例)。對照組靜脈注射阿加曲班注射液,10 mg/次加入生理鹽水100mL,2h內(nèi)靜脈滴注完畢,2次/d。治療組患者在對照組基礎(chǔ)上口服地奧司明片,2片/次,4次/d。兩組患者治療10 d。觀察兩組患者臨床療效,比較治療前后兩組患者癥狀緩解時間,靜脈血管再通暢率,血清因子腫瘤壞死因子-α(TNF-α)、D-二聚體(D-D)、C反應(yīng)蛋白(CRP)和白細(xì)胞介素-6(IL-6)水平,及不良反應(yīng)。結(jié)果 治療后,治療組患者臨床有效率為97.50%,明顯高于對照組(77.51%,P<0.05)。治療后,治療組患者癥狀好轉(zhuǎn)時間均短于對照組(P<0.05)。治療后,治療組患者靜脈血管再通暢率明顯高于對照組(P<0.05)。治療后,兩組血清因子IL-6、D-D、TNF-α、CRP水平明顯降低(P<0.05),且治療后治療組明顯低于對照組(P<0.05)。治療組不良反應(yīng)發(fā)生率(7.50%)明顯低于對照組(22.50%,P<0.05)。結(jié)論 地奧司明聯(lián)合阿加曲班治療下肢深靜脈血栓效果確切,血管再通暢改善明顯,顯著降低炎性因子含量,且安全有效。

Objective To investigate the clinical efficacy of diosmin combined with argatroban in treatment of lower extremity deep vein thrombosis. Methods Patients (80 cases) with lower extremity deep vein thrombosis in Jincheng People’s Hospital from June 2021 to June 2022 were randomly divided into control (40 cases) and treatment (40 cases) group. Patients in the control group were iv administered with Argatroban Injection, 10 mg/time added into normal saline 100 mL, which was completed within 2 h, twice daily. Patients in the treatment group po administered with Diosmin Tablets on the basis of the control group, 2 tablets/time, four times daily. Patients in two groups were treated for 10 d. After treatment, the clinical evaluation was evaluated, the relief time of symptom, the venous recanalization rates，the levels of serum inflammatory factor IL-6, D-D, TNF-α and CRP, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was 97.50%, which was significantly higher than that in the control group (77.51%, P＜0.05). After treatment, the time of symptom improvement in the treatment group was shorter than that in the control group (P＜0.05). After treatment, the recanalization rate of venous vessels in the treatment group was significantly higher than that in the control group (P＜0.05). After treatment, the serum levels of IL-6, D-D, TNF-α and CRP in two groups were significantly decreased (P＜0.05), and which in the treatment group were significantly lower than those in the control group (P＜0.05). The incidence of adverse reactions in the treatment group (7.50%) was significantly lower than that in the control group (22.50%, P＜0.05). Conclusion Diosmin combined with argatroban has exact effect in treatment of lower extremity deep vein thrombosis, and the patency of blood vessels is improved obviously, the content of inflammatory factors is significantly reduced, and which is safe and effective.

R914